Reports Q1 revenue $150.8M, consensus $146.56M. “We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue,” said Serge Saxonov, Co-founder and CEO of 10x Genomics (TXG). “The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $32 from $22 at Canaccord
- 10x Genomics price target raised to $30 from $21 at BofA
- 10x Genomics announces Atera, a new in situ spatial biology platform
- 10x Genomics price target raised to $30 from $22 at Barclays
- 10x Genomics price target raised to $24 from $18 at Citi